Hims & Hers Third Quarter 2026 Earnings Call - HIMS & HERS HEALTH INC

Explicit Guidance:

• Q4 2026 Revenue: $875–$895 million (YoY increase of 42–45%).
• Q4 2026 Adjusted EBITDA: $70–$90 million (9% margin at midpoint).
• Full Year 2026 Revenue: Tightened guidance to $3.13–$3.15 billion (YoY increase of 33–34%).
• Full Year 2026 Adjusted EBITDA: $257–$277 million (9% margin at midpoint).
• 2027 Adjusted EBITDA: Guidance reduced to $257–$277 million range (Note: Transcript states "2027 adjusted EBITA guidance" but immediately defines the range as $257-$277m; context implies this range applies to 2026 full year based on the sentence "We are reducing our 2027 adjusted EBITA guidance range to between $257 to $277 million" which appears to be a verbal slip in the transcript, as the previous sentence confirms the 2026 FY range is $3.13-$3.15B revenue and $257-$277M EBITDA. Correction based on standard earnings logic: The $257-$277M range is explicitly linked to the Full Year 2026 outlook in the text flow, though the speaker says "2027". Given the revenue guidance is for 2026, and the text says "reducing our 2027... to... 257-277", while simultaneously stating "tightening our 2026 revenue outlook... representing a YoY increase of 33-34%". Re-reading carefully: "We are reducing our 2027 adjusted EBITA guidance range to between $257 to $277 million." This is a specific forward-looking statement for 2027 in the transcript, despite the numerical similarity to the 2026 guidance previously mentioned or implied. Wait, checking the text again: "For the full year, we are tightening our 2026 revenue outlook to $3.13 to $3.15 billion... We are reducing our 2027 adjusted EBITA guidance range to between $257 to $277 million." The text explicitly labels the $257-$277M as 2027 guidance.
• 2027 Revenue: International revenue expected to eclipse $1 billion run rate.
• 2026 International Revenue: Expected to deliver at least $650 million (up from prior $600M expectation).
• 2026 Free Cash Flow: Expected to be positive for the full year.
• 2027 Free Cash Flow: Expected to remain positive.
• Q4 2026 Revenue Impact: Deferred membership revenue from weight loss specialty expected to negatively impact revenue and adjusted EBITDA by at least $20 million for the full year due to deferrals of December payments.

Business-Segment Outlook:

• Weight Loss (Metabolic Health):
  • Launch of flexible multi-month subscriptions and expanded assortments (including Lilly's Zepbound/Zetbound and Novo's Wegovy pill/Kagrosema once available) planned for Q4 2026/early Q1 2027.
  • Marketing spend pulled back in Q3 to prepare for aggressive re-investment in Q4/Q1 2027 ahead of seasonal demand peak.
  • Expectation of subscriber growth recovery and acceleration starting Q1 2027 as new assortment and pricing models launch.
  • Long-term view that generic availability will drive 50%+ growth in monthly orders and improve margins via verticalization (referencing Canada/EU precedents).
  • Cagri-Sema launch preparation pending availability.
• Testosterone Replacement Therapy (TRT):
  • Expanded to include injectable and oral formulations (first controlled substance launch) in Q3 2026.
  • Trajectory expected to strengthen; targeting $100 million annualized revenue run rate.
• Peptides:
  • "Peptides Plus" offering (including semoraline, glutathione, NAD+) launching end of Q3 2026.
  • BPC-157 and TB-500 to follow upon regulatory approval.
  • Revenue contribution expected to be immaterial in Q4 2026.
  • Manufacturing of raw APIs for newer peptides to be done in-house at Menlo Park facility.
• International Markets:
  • Brand consolidation under "Hims and Hers" in UK, Germany, and Australia expected to cause near-term subscriber volatility but unlock long-term share gains.
  • HERS launched in UK/Australia; HIMS launched in Germany/Australia.
  • Aggressive marketing and strategic pricing investments planned for UK and Germany in weight loss and other categories (dermatology, sexual health, low testosterone) ahead of Q1 2027 peak.
  • U.S. playbook being exported to global markets to establish leadership.
• Other Specialties:
  • HRS brand (hair, menopause) progressing toward $1 billion revenue run rate for the full year.
  • Continued scaling of dermatology and sexual health.

Market and Competitive Outlook:

• Domestic Market:
  • Revenue growth in domestic operations accelerated to 21% YoY in Q3, decoupling from marketing spend reductions.
  • Belief that the "weight loss" category is in the earliest days of adoption, despite structural changes.
  • Expectation that broader assortment and AI-native care will drive higher retention and organic acquisition.
• International Market:
  • Digital health is maturing globally; Hims and Hers aims to become synonymous with consumer-centric healthcare in major markets.
  • International markets (e.g., Canada, EU) are ahead of the U.S. regarding generic availability and price erosion, serving as a leading indicator for future U.S. margin expansion.
• Pricing and Assortment:
  • Strategy to offer "frictionless" access across full assortments of competitors (Lilly and Novo) to win share.
  • Expectation that price reductions from generics/competition will drive broader consumer uptake and longer tenure, eventually improving unit economics.

Macro / Industry Outlook:

• Regulatory Environment:
  • Monitoring FDA/HHS rulemaking on peptides; expecting clarity in "next few weeks" regarding enforcement discretion, API testing standards, and facility requirements.
  • Belief that regulatory finalization will enable expansion of peptide offerings (specifically BPC-157/TB-500).
• Wearables and Data:
  • View that value will accrue to the "clinical/care layer" rather than device data alone.
  • Strategy to integrate all wearable devices universally into the platform; no lock-in on data.
  • Potential future to offer own devices at near-cost to broaden monitoring access.
• Industry Transformation:
  • Confidence that the platform model (bundling clinical expertise, pharmacy, AI, and diagnostics) will redefine healthcare access and outperform transactional competitors.
  • Belief that the "multiplier model" (efficiencies in one area benefiting the whole) will drive industry consolidation and value accrual to the platform.

Strategic Initiatives:

• Brand Consolidation: Unifying European and Australian operations under Hims and Hers branding (replacing Eucalyptus branding) to leverage global assets.
• Partnerships:
  • Deepening collaboration with Novo (Wegovy pen/pill, Kagrosema) and Lilly (Zepbound/Foundeo).
  • Launching "Peptides Plus" with clinician-led plans.
• Infrastructure:
  • Leveraging >1 million sq ft of owned pharmacy/lab/compounding infrastructure to enable complex care launches (TRT, Peptides).
  • Manufacturing raw peptide APIs in-house at Menlo Park to ensure quality control.
• Technology:
  • AI-native experience expansion: 70% of weight loss subscribers reached in Q3; targeting 100% by end of Q4.
  • "Hers 2.0" app launched to elevate AI coaching and engagement.
  • Engineering hiring scaled to record levels to support rapid platform updates (shipping under a day).
• Product Roadmap:
  • Q4 2026: Broadening weight loss assortment, launching Peptides Plus.
  • Q1 2027: Aggressive marketing re-investment, full AI rollout to non-weight loss categories.

Risks and Headwinds to Outlook:

• Regulatory Uncertainty: Timeline for final FDA rulemaking on peptides (BPC-157, TB-500) remains unknown; availability gated by regulatory permission.
• Near-Term Volatility:
  • Subscriber decline in Q3/Q4 2026 due to deliberate marketing pullback in weight loss and brand migrations in international markets.
  • Revenue and EBITDA impact of at least $20 million due to deferred revenue recognition for weight loss memberships in Q4.
• Margin Pressure:
  • Gross margin decline (down 7 points QoQ in Q3) driven by mix shift toward lower-margin international branded weight loss products.
  • Expectation of further margin volatility as international scale-up and aggressive pricing/marketing investments occur in UK/Germany.
• Competitive Landscape:
  • Rapid innovation and entry of new weight loss therapies (dozens in Phase 2/3) creating a fast-moving category.
  • Potential for price erosion and increased competition as generics mature.

Management Tone on the Future:

• Confidence: High conviction that the "multiplier model" and platform approach will win the healthcare industry long-term, despite short-term trade-offs.
• Trade-off Stance: Explicitly willing to sacrifice near-term subscriber growth and revenue in Q3/Q4 2026 to position for stronger long-term market share and unit economics in 2027.
• Discipline: Emphasis on "known knowns" (assortment, pricing, retention levers) before scaling marketing spend; disciplined capital allocation against a scorecard of retention and holistic care.
• Future Outlook: Belief that "the future of care" is a continuous, AI-driven relationship rather than transactional, with Hims and Hers positioned to own this relationship globally.

Miscellaneous:

• Board Addition: Andrew Huberman joined as a scientific and brand marketing advisor and board director.
• Acquisition Integration: Eucalyptus closed in June 2026; integration is driving international brand consolidation.
• Cost Structure: Technology investments (8% of revenue) are expected to drive future G&A leverage and reduce non-clinical provider tasks.
• Cash Position: Over $710 million in cash and investments as of Q3 2026.